BREYANZI is a prescription medicine used to treat large B cell lymphoma, a type of non-Hodgkin lymphoma, when:

  • your first treatment has not worked or your cancer returned within a year of your first treatment OR...Read more

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Real stories powered by real people

Karla’s Breyanzi® story

Karla, a Breyanzi® (lisocabtagene maraleucel) patient

Karla was part of the Breyanzi clinical trial, and the FDA approved Breyanzi for use after a patient’s first treatment in June 2022.

Karla’s Breyanzi® story

When Breyanzi was given to me as an option, I was unsure. And now that I've done it, I know I did the right thing for me. I'm the living, breathing proof of it. It worked for me.

—Karla